Related Experiment Video
Updated: Aug 11, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
[Glutathione in the treatment of chronic fatty liver diseases]
P Dentico1, A Volpe, R Buongiorno
1Istituto Policattedra, Università, Bari.
Abstract:
In chronic steatosic liver disease, alcohol or non-alcohol related or HBV, HCV, HDV associated, a reduction in hepatic glutathione and, consequently, in the detoxifying effects of hepatocytes is observed. Intravenous administration of high dose glutathione in patients with chronic steatosic liver disease has shown that glutathione significantly improves the rate of some hepatic tests (bilirubin, GOT, GPT, GT) even several months after treatment interruption. Further confirmation of the efficacy of GSH treatment is provided by the reduction of malondialdehyde, a marker of hepatic cell damage. The optimal results obtained in patients receiving 1800 mg/die/i.v. advocate the use of this high dosage.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

